Glucocorticosteroid in Treatment of Severe Pneumonia
Airway diseases such as pneumonia constitute a major health burden on a global scale; untreated pneumonia may develop to severe pneumonia and consequently lead to to fatal episodes of mortality and morbidity. The balance between inflammatory mediators is key for the outcome of the pulmonary infectio...
Saved in:
Main Authors: | Felinda Ariani, Kaixiong Liu, Zhang Jing, Jieming Qu |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2013-01-01
|
Series: | Mediators of Inflammation |
Online Access: | http://dx.doi.org/10.1155/2013/865635 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
A Severe Case of Ipilimumab-Induced Ileocolitis Refractory to Glucocorticosteroids and Infliximab
by: Behdod Poushanchi, et al.
Published: (2018-01-01) -
The use of oral topically acting glucocorticosteroids in the treatment of
inflammatory bowel disease
by: P. Rutgeerts
Published: (1998-01-01) -
Glucocorticosteroids and the Risk of NAFLD in Inflammatory Bowel Disease
by: Sara Jarmakiewicz-Czaja, et al.
Published: (2022-01-01) -
Overview of Newer Glucocorticosteroid Preparations for Inflammatory Bowel Disease
by: R Brattsand
Published: (1990-01-01) -
Experience with the use of glucocorticosteroid implants in patients with macular edema associated with sarcoidosis.
by: V.A. Pavlov, et al.
Published: (2022-09-01)